ARE. Spec Pharma (-) — =eadwinds remain w/ Sumant's top =ick AGN =iven lower risk to reimbursement pressures & an underappreciated =ipeline. =/span>Leverage & CF remain the key focus for investors. Tools/Animal Health ==) — Derik notes more "headline" than =E244oreal" risks from policy which will create oppo